Michael Yang, CEO San Diego, CA (Private) In-person Presentation ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells, and medical device systems for cell encapsulation and implantation. ViaCyte has the...

Petter Björquist, Ph.D., CEO Göteborg, Sweden (Private) In-person Presentation VERIGRAFT is a Swedish biotechnology company run by experienced entrepreneurs and mastering a unique, breakthrough technology in the field of advanced therapies and regenerative medicine. We make transplantation possible without the severe risks of immunosuppression, and develop advanced therapies and...

Carter Cliff, Founder and CEO Madison, WI (Private) In-person Presentation Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death, for whom few to no treatment...

Jonathan Garen, Chief Business Officer Amsterdam, Netherlands (NASDAQ: QURE) In-person Presentation uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat...

Kevin Alessandri, Ph.D., Chief Technology Officer and Vice President, USA Pessac, France (Private) In-person Presentation TreeFrog Therapeutics is a French biotech company aiming to provide access to safe and affordable cell therapies for millions of patients. Using proprietary C-Stem technology, TreeFrog Therapeutics announced in April 2021 the production of...

Antoinette Gawin, CEO Lakewood, CO (Private) In-person Presentation Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis, and cellular therapy technologies, believes in the potential of blood and cells to do even more for patients than they do today. Our business enables researchers, developers, and...

Faraz Ali, CEO San Francisco, CA (Private) In-person Presentation Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern...

Scott Requadt, CEO Louisville, KY (NASDAQ: TALS) In-person Presentation Talaris Therapeutics is a late clinical-stage, publicly traded biotechnology company that is developing a one-time cell therapy that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant immune...

Philip Toleikis, Ph.D., President and CEO London, Canada (NASDAQ: SEOVF) In-person Presentation Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including...

Brian Miller, Co-Founder and CEO Lexington, MA (Private) In-person Presentation Sentien Biotechnologies is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells within an extracorporeal, hollow-fiber device. By immobilizing MSCs within...

By using this website you agree to accept our Privacy Policy and Terms & Conditions